CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY

Código QR

CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY

.

Guardado en:

Detalles Bibliográficos
Autor principal:	A. Budkowska
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2018
Materias:	Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/1d3c81e9d5f844aa8d77430c2378cbda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

DEVELOPMENT AND APPROBATION METHOD OF IDENTIFICATION MUTATIONS THE RESISTANCE OF THE HEPATITIS C VIRUS TO DIRECT-ACTING ANTIVIRAL AGENTS (DAAs)
por: D. E. Valutite, et al.
Publicado: (2018)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
por: Ibrahim Anam Ezzelregal, et al.
Publicado: (2020)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Monica Basso, et al.
Publicado: (2021)

‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant
por: Fabrizio Fabrizi, et al.
Publicado: (2021)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
por: Cesare Mazzaro, et al.
Publicado: (2021)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
por: Stefania Farcomeni, et al.
Publicado: (2021)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
por: Fei Xiao, et al.
Publicado: (2014)

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
por: V. Stalin Raj, et al.
Publicado: (2017)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Atsushi Hosui, et al.
Publicado: (2021)

Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis
por: Rosanna Villani, et al.
Publicado: (2021)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
por: María E. Cárdaba-García, et al.
Publicado: (2021)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla M, et al.
Publicado: (2019)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
por: Mercedes Márquez-Coello, et al.
Publicado: (2021)

Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.
por: Patrick Maillard, et al.
Publicado: (2011)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Kao-Chi Chang, et al.
Publicado: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen M, et al.
Publicado: (2017)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
por: Meritxell Llorens-Revull, et al.
Publicado: (2021)

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
por: Omar A. Saldarriaga, et al.
Publicado: (2021)

Assessment of Left Ventricular Systolic Function by Speckle Tracking in Diabetic Patients Receiving Direct Acting Antiviral Drugs for Chronic HCV
por: Wael Hassib, et al.
Publicado: (2021)

HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization
por: Daniel Valle-Millares, et al.
Publicado: (2022)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Yoshimasa Tokuchi, et al.
Publicado: (2021)

Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes.
por: Matthew A Burchill, et al.
Publicado: (2021)

Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity
por: Tarek Yosef, et al.
Publicado: (2021)

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
por: Bambang S Adiwijaya, et al.
Publicado: (2012)

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022)

L3 Skeletal Muscle Index Dynamics in Patients with HCV-Related Compensated Cirrhosis Following Sustained Virological Response after Direct Acting Antiviral Treatment
por: Florin Mihai, et al.
Publicado: (2021)

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
por: Heng Lee, et al.
Publicado: (2021)

Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report
por: Yumiko Nagao, et al.
Publicado: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Naoki Kawagishi, et al.
Publicado: (2021)

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
por: Hung-Yin Liu, et al.
Publicado: (2021)

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan
por: Chun-Ming Hong, et al.
Publicado: (2021)

The role of PTEN - HCV core interaction in hepatitis C virus replication
por: Qi Wu, et al.
Publicado: (2017)

Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.
por: Stéphane Chevaliez, et al.
Publicado: (2009)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
por: Elabd NS, et al.
Publicado: (2021)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)